@article{oai:repo.qst.go.jp:00044880,
 author = {Nakamura, Kazutaka and Yamaguti, Taketo and Ishihara, Takeshi and Kobayashi, Akitoshi and Tadenuma, Hiroshi and Sudo, Kentaro and Katou, Hirotoshi and Saisho, Hiromitsu and 山口 武人 and 加藤 博敏 and 税所 宏光},
 issue = {11},
 journal = {British Journal of Cancer},
 month = {Jun},
 note = {We conducted a phase II trial of gemcitabine with S-1, oral fluorouracil (5-FU) prodrug tegafur combined with two modulators, 5-chloro-2, 4-dihydroxypyridine and potassium oxonate, to evaluate the activity and toxicity of such a combination in metastatic pancreatic cancer (MPC) patients. Patients who had pathologically proven pancreatic cancer with metastatic lesions were eligible candidates for entry into the study. S-1 was given orally (30 mg m(-2)) b.i.d. for 14 consecutive days and gemcitabine (1000 mg m(-2)) was given on days 8 and 15. The cycle was repeated every 21 days. We enrolled 33 MPC patients. The median number of cycles was eight (range 1-20). Grade 3-4 toxicities were leucopenia (33%), neutropenia (55%), anaemia (9%), thrombocytopenia (15%), anorexia (6%), fever (9%), and interstitial pneumonia (6%). Objective responses were obtained in 16 patients (one complete response and 15 partial responses; response rate, 48%; 95% confidence interval (CI), 33-65). Median survival and 1-year survival rate were 12.5 months (95% CI, 5.9-19.1) and 54% (95% CI, 36-72), respectively. Combination chemotherapy with GEM and S-1 was well tolerated and yielded a significantly high response rate.},
 pages = {1575--1579},
 title = {Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer},
 volume = {94},
 year = {2006}
}